Eight months after announcing the $18.5 million first tranche of its series A, Augustine Therapeutics has closed the oversubscribed round at $85 million and is now ready to begin clinical development ...

Augustine’s approach focuses on inhibiting the cytosolic histone deacetylase 6 (HDAC6) enzyme, which plays a key role in neurodegeneration and aging-related cellular processes. The company’s ...

HDAC6 is involved in neurodegeneration and tissue aging-related cellular processes, and pharmacologic inhibition of HDAC6 is a promising approach in a number of diseases. Augustine Therapeutics ...